Poster Presentations Session II
Poster Presentations Session II Sunday, 17 September 2017
POSTERS SET-UP: 7:45 - 8:00
POSTERS DISPLAY HOURS: 8:00 - 14:00
POSTER AUTHOR DISCUSSION: 13:00 - 14:00
POSTERS DISMANTLE: 14:00


Poster display locations are shown below the poster codes
DIABETES/ENDOCRINE DISORDERS - Clinical Outcomes Studies
PDB1
F8
GLYCEMIC CONTROL IN PATIENTS WITH T2DM TREATED WITH SULFONYLUREAS ALONE OR IN COMBINATION WITH METFORMIN, ARGENTINA
Gonzalez CD1, Monti CI2, Pinzon A3, Monsanto H4, Ejzykowicz F5
1Merck & Co, Inc., Kenilworth, NJ, USA, 2MSD Argentina, Munro, Buenos Aires, Argentina, 3MSD (IA) Corp - CL Branch, Santiago, Chile, 4Merck Sharp & Dohme (IA) LLC, Carolina, PR, USA, 5Merck & Co, Inc., North Wales, PA, USA

PDB2
F9
GROWTH FACTORS FOR THE MANAGEMENT OF DIABETIC FOOT ULCERS: MIXED TREATMENT COMPARISONS OF RANDOMIZED CONTROLLED TRIALS
Sridharan K1, Sivaramakrishnan G2
1Fiji National University, Suva, Fiji, 2Fiji National University, Suva, Fiji, Fiji

PDB3
F10
DATABASE ANALYSIS OF A SUPPORT PROGRAM FOR PEDIATRIC PATIENTS USING SOMATROPIN DUE TO GROWTH HORMONE DEFICIENCY (GHD)
Biglia LV, Seiler P, Souza PV
Merck, São Paulo, Brazil

PDB4
F11
EVALUATION OF SMOKING PREVALENCE AND ITS ASSOCIATED FACTORS AMONG THE DIABETICS IN PAKISTAN
Gillani AH1, Aziz MM1, Bashir S2, Mustafa A3, Fang Y1
1Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China, Xi'an, China, 2Quaid E Azam medical college Bahawalpur Pakistan, Bahawalpur, Pakistan, 3Islamia University of Bahawalpur, Bahawalpr, Pakistan

DIABETES/ENDOCRINE DISORDERS - Cost Studies
PDB5
F12
COST-MINIMIZATION OF SOMATROPIN FOR GH DEFICIENCY AND TURNER SYNDROME TREATMENT FROM SUS PERSPECTIVE
Souza PV, Biglia LV, Zanini FE
Merck, São Paulo, Brazil

PDB6
F13
THE ECONOMIC IMPACT OF OPTIMIZING THERAPY IN ‘HARD-TO-TREAT’ AND ‘HARDER-TO-TREAT’ HYPOTHYROID PATIENTS BY CHANGING THE LEVOTHYROXINE FORMULATION FROM TABLETS TO GEL CAPS
Carter C1, Elmor R2, Sandulli W3
1CPHS, Campbell University, Buies Creek, NC, USA, 2Indegene, Inc, Kennesaw, GA, USA, 3Akrimax Pharmaceutical, LLC, Cranford, NJ, USA

PDB7
F14
IMPACTO ECONÓMICO DE LA HIPOGLUCEMIA EN COLOMBIA
Romero Prada ME1, Pajaro A1, Alfonso Quiñones PA2
1Fundación Salutia, Bogotá, Colombia, 2Salutia Foundation, Bogotá, Colombia

PDB8
F15
COSTOS DE LA HIPOGLUCEMIA EN COLOMBIA
Romero Prada ME1, Pajaro A1, Alfonso Quiñones PA2
1Fundación Salutia, Bogotá, Colombia, 2Salutia Foundation, Bogotá, Colombia

PDB9
F16
COSTO DE LA DIABETES MELLITUS EN EL SISTEMA DE SALUD COLOMBIANO
Acuña L1, Bryón A2, Aschner P3, Chica LG4, Espin J5, Jaimes D6, Londoño D7, Lopez R6, Ruiz A3, Soler L8
1Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia, 2HEORT- Health Economics & Outcomes Research Team, Bogota, Colombia, 3Pontificia Universidad Javeriana Medical School, Bogota, Colombia, 4Fundación Santa Fé de Bogotá, Bogota, Colombia, 5Andalusian School of Public Health, Granada, Spain, 6HEORT, Bogota, Colombia, 7Fundacion Santa Fe de Bogota, Bogota, Colombia, 8Risk Management Cordinator, Fondo Colombiano de Enfermedades de Alto Costo, Bogota, Colombia

PDB10
F17
COSTS OF MANAGING HYPOGLYCAEMIAS AMONG INSULIN-TREATED PATIENTS WITH DIABETES: RESULTS FROM THE HAT STUDY IN BRAZIL
Lamounier RN1, Ermetice MN2, Griciunas F2, Silva C3
1Centro de Diabetes de Belo Horizonte, Belo Horizonte, Brazil, 2Novo Nordisk, São Paulo, Brazil, 3Eurotrials - Scientific Consultants, Lisbon, Portugal

PDB11
F18
EVOLUTION COST-EFFECTIVENESS ANALYSIS OF PHARMACEUTICAL CARE FOR TYPE 2 DIABETES MELLITUS
Picoli RM, Pereira LB, Nunes AA, Pereira LR, Costa AL
University of São Paulo, Ribeirão Preto, Brazil

DIABETES/ENDOCRINE DISORDERS - Patient-Reported Outcomes & Patient Preference Studies
PDB12
G1
IS TRANSTHEORETICAL MODEL’S STAGES OF CHANGE A GOOD PREDICTOR OF MEDICATION ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES?
Arafat Y1, Mohamed Ibrahim MI1, Awaisu A2, Colagiuri S3, Owusu Y1, Morisky DE4, AlHafiz M5, Yousif A5
1Qatar University, Doha, Qatar, 2Qatar University College of Pharmacy, Doha, Qatar, 3The University of Sydney, Sydney, Australia, 4UCLA Fielding School of Public Health, Los Angeles, CA, USA, 5Primary Health Care Corporation, Doha, Qatar

PDB13
G2
DIABETES MELLITUS ADHERENCE TO CLINICAL FOLLOW-UP, BASED IN LOCAL GUIDELINES AND METABOLICAL OUTCOMES
Uribe Parra D1, Soler LA1, Lizbeth AM1, Jaimes D2, Bryón A3, Aschner P4, Chica LG5, Ruiz Morales A6
1Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia, 2HEORT, Bogota, Colombia, 3HEORT- Health Economics & Outcomes Research Team, Bogota, Colombia, 4Pontificia Universidad Javeriana Medical School, Bogota, Colombia, 5Fundación Santa Fé de Bogotá, Bogota, Colombia, 6Pontifica Universidad Javeriana Medical School, Bogota, Colombia

PDB14
G3
FOLLOW-UP OF PEDIATRIC PATIENTS UNDER TREATMENT WITH SOMATROPIN IN BRAZIL THROUGH A PATIENT SUPPORT PROGRAM (PSP)
Seiler P, Guimaraes F, Biglia LV, Souza PV
Merck, São Paulo, Brazil

PDB15
G4
IMPACT OF WEIGHT LOSS (WL) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AMONG LATIN AMERICAN (LA) SUBJECTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN PHASE 3 STUDIES OF CANAGLIFLOZIN (CANA)
Soares B1, Akapame S2, Cabrera P3, Slee A2, Traina S4, Magno L5
1Janssen-Cilag Farmacêutica Ltda, São Paulo, Brazil, 2Axio Research, Seattle, WA, USA, 3Janssen Colombia, Bogotá, Colombia, 4Janssen Global Services, LLC, Raritan, NJ, USA, 5Janssen Global Services, LLC, Titusville, NJ, USA

DIABETES/ENDOCRINE DISORDERS - Health Care Use & Policy Studies
PDB16
G5
EVOLUCIÓN DE LA CALIDAD DE ATENCIÓN EN PERSONAS CON DIABETES TIPO 2 (DMT2) DE ARGENTINA: RESULTADOS DEL INTERNATIONAL DIABETES MANAGEMENT PRACTICES STUDY (IDMPS)
Elgart JF1, Forti L2, De luca J2, Guaita MS2, Gagliardino JJ1
1CENEXA. Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET), La Plata, Argentina, 2Sanofi, Buenos Aires, Argentina

PDB17
G6
FINANCIAMIENTO DEL CRIBADO Y TRATAMIENTO DE LA NEFROPATÍA DIABÉTICA EN EL PRIMER NIVEL DE ATENCIÓN POR EL SEGURO INTEGRAL DE SALUD, PERÚ
Flores-Benites VV1, Comesaña-Reyes RE1, Zeta-Ruiz Nd2, Gendrau-Castillo LJ2
1Fondo Intangible Solidario de Salud, Lima, Peru, 2Universidad Nacional Mayor de San Marcos, Lima, Peru

PDB18
G7
REAL-WORLD DATA (RWD) ON THE ATTAINMENT OF COMPOSITE QUALITY MEASURES (CQM) IN A BRAZILIAN POPULATION WITH SELF-REPORTED TYPE-2 DIABETES MELLITUS (T2DM)
Ferreira KA1, Winget M2, Sposito A3, Machnicki G4, Cabrera P5, Liebert R6, Neslusan C7, Flores N8, Soares B1, Coutinho W9, Magno L10
1Janssen-Cilag Farmacêutica Ltda, São Paulo, Brazil, 2Kantar Health, St. Louis, MO, USA, 3University of Campinas - UNICAMP, Campinas, SP, Brazil, 4Janssen Argentina, Buenos Aires, Argentina, 5Janssen Colombia, Bogotá, Colombia, 6Kantar Health, New York, NY, USA, 7Janssen Global Services, LLC, Raritan, NJ, USA, 8Kantar Health, Foster City, CA, USA, 9Pontificia Universidade Catolica do Rio de Janeiro, Rio de Janeiro, Brazil, 10Janssen Global Services, LLC, Titusville, NJ, USA

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.